Anti-abeta antibody
AssigneeEli Lilly and Company
InventorsRonald DeMaattos, Uma Kuchibhotia, Hsiu-Chiung Yang, Don McClure
Life of this patent
Estimating the term…
Abstract
This present invention provides a composition that is suitable for administration to a human subject comprising an anti-Aβ antibody that is free of Aβ peptide or that has acceptably low levels thereof, free of non-human Aβ peptide or that has acceptably low levels thereof, or having an undetectable concentration of Aβ peptide.
Claims8
1-15. (canceled)
A pharmaceutical composition suitable for administration to a human subject comprising a purified abeta antibody wherein the antibody is expressed in a cell line that endogenously produces an abeta peptide and wherein the antibody purified from such cell line has an undetectable concentration of or has acceptably low levels of endogenously produced abeta peptide.
A process for preparing an abeta antibody comprising the steps of:
- a. expressing the antibody in cells that endogenously express abeta peptide;
- b. adding a beta or gamma secretase inhibitor to media used to grow the cells;
- and
- c. purifying the antibody from the growth media wherein the purified antibody has an undectable concentration or has acceptably low levels of endogenously produced abeta peptide.
A process for preparing an abeta antibody comprising the steps of:
- a. expressing the antibody in cells that endogenously produce abeta peptide;
- b. increasing alpha-secretase activity in such cells;
- c. purifying the antibody from the media used to grow the cells wherein the purified antibody has an undetectable concentration or has acceptably low levels of endogenously produced abeta peptide.
Dependencies are inferred from the claim text.